Intracardiac Thrombus and Sources of Embolism

Intracardiac thrombus completes the three-way differential this section’s framework page establishes — tumor, thrombus, or vegetation — and genuinely deserves its own page, since thrombus is the one category where chamber location itself dictates which imaging modality to trust. See Approach to Cardiac Masses for the foundational confirmation framework, and Cardiac Tumors for the tumor side of the same differential, that this page builds directly on.

The Organizing Principle: Modality Preference Reverses by Chamber

This is worth establishing before anything else, since it genuinely shapes how every section below should be read: the preferred imaging modality for thrombus detection is not the same across chambers, and the pattern reverses depending on location.

Location	Preferred modality	TTE sensitivity	TEE sensitivity
LV	TTE (procedure of choice)	~95%	~40% (apex often missed)
LA	TEE	Very poor	High
RA	TEE	~60%	~97%

For LV thrombus, TTE is genuinely the clinical procedure of choice, and TEE is rarely helpful — standard TEE views frequently miss the true apex given its near-field geometry from the esophageal approach. For LA and RA thrombus, that relationship flips entirely: TTE’s sensitivity is poor enough that a negative transthoracic study never excludes the diagnosis when clinical suspicion is genuine, and TEE becomes the appropriate procedure whenever the presence or absence of thrombus will actually change management.

LV Thrombus

Predisposing Conditions: Stasis Is the Prerequisite

LV thrombus forms in regions of blood stasis or low-velocity flow, and formation is extremely rare without an akinetic or dyskinetic apex, or diffuse LV systolic dysfunction — thrombus doesn’t appear in a well-contracting ventricle without a flow-stasis substrate to explain it. The classic example is a ventricular aneurysm, with low-velocity swirling flow; similar stasis occurs with lesser segmental wall motion abnormalities (apical akinesis) and with diffuse dysfunction as in dilated cardiomyopathy. An LV pseudoaneurysm is almost invariably accompanied by thrombus lining the ruptured, pericardially-contained cavity.

Timing and incidence after acute MI: thrombus can be seen as early as 24 hours post-infarction; about 90% form within the first 2 weeks, though formation within the first 3 months is possible. Reported incidence after AMI ranges from 7% to 46% depending on detection modality, but incidence has genuinely declined in the primary PCI era, now reported between 5% and 15%. LV thrombus occurs more often after LAD-territory infarction than other territories; about 11% of clots occur in the septal wall and 3% in the inferior wall when the infarct extends to the lateral wall. See Acute Myocardial Infarction for the broader acute assessment this screening step fits into.

In cardiomyopathy specifically, an EF under 20% carries the single highest reported risk — an incidence approaching 50%. Genuinely worth knowing: mitral regurgitation appears protective against LV thrombus in cardiomyopathy patients, presumably because the regurgitant jet itself disrupts the area of stasis — though this same protective association has not been demonstrated after acute MI specifically.

A comprehensive list of predisposing conditions, organized by whether LV function is impaired or preserved:

LV function impaired (more common)	LV function preserved (extremely rare)
LV apical aneurysm	Eosinophilic endocarditis
Post-MI apical akinesis	Hypercoagulable states (antiphospholipid antibody, protein C deficiency, myeloproliferative disorders, essential thrombocythemia, myelofibrosis)
Post-MI in non-LAD territory	Salmonella septicemia
LV pseudoaneurysm	Cardiac trauma
Dilated cardiomyopathy	Connective tissue disease (SLE, Behçet disease)
Apical ballooning (Takotsubo) syndrome	On the surface of LV tumors; device leads migrating to the LV; large-dose erythropoietin

Identification

Sensitivity and specificity of TTE for LV thrombus are both high — about 95% and 85–90% respectively — but achieving this requires technique, not just a standard study: angulated apical views in addition to the four-chamber view, apical short-axis obtained by moving the transducer slightly laterally while angulating anteriorly, and a 5- or 7.5-MHz short-focus transducer to optimize near-field resolution. Scanning across the apex in several views reliably distinguishes a true thrombus from prominent apical trabeculations or false tendons — bright linear structures attached to mural trabeculae, rather than a discrete mass with its own contour. Contrast opacification of the LV genuinely improves apical thrombus detection and should be used whenever clinical or imaging findings raise concern — in one illustrative example, no clot was visible on a non-contrast image despite anterior MI and poor endocardial definition, while contrast administration revealed a clearly avascular apical clot with no uptake.

The diagnosis is most secure when all of the following are present: an echogenic mass with a convex surface that is not a reverberation (“ring-down”) artifact, clearly distinct from the endocardium, and located in a region of abnormal wall motion. A laminated thrombus is harder to identify with confidence unless a clear demarcation from the underlying myocardium is visible — it can be suspected when the apex appears “rounded” and akinetic with apparently excessive apical wall thickness, since layered thrombus itself produces this pseudo-thickened appearance.

Clinical Implications and Risk Stratification by Morphology

LV thrombus is a strong predictor of subsequent embolic events — particularly when it protrudes into the cavity or shows independent mobility. A sessile, nonprotruding thrombus carries lower embolic potential by comparison — morphology, not simply presence or absence, is what should drive the clinical conversation about risk. When apical images remain suboptimal despite careful technique and contrast use, a definite exclusion of apical thrombus genuinely may not be possible, and this limitation is worth stating plainly rather than implying false reassurance.

LA Thrombus

Predisposing Factors

LA thrombi form with blood flow stasis, associated with atrial enlargement, mitral valve disease, and atrial fibrillation. The highest incidence occurs with the combination of rheumatic mitral stenosis and atrial fibrillation together — though even patients in sinus rhythm with only modest LA enlargement can develop thrombus if mitral stenosis or poor LV function is present. LA thrombi are genuinely less common with mitral regurgitation, presumably for the same mechanical reason MR is protective for LV thrombus — the high-velocity regurgitant jet disrupts the area of stasis that would otherwise allow thrombus to form.

Identification

TEE is the appropriate procedure whenever LA thrombus presence or absence will genuinely affect management. The LA appendage is evaluated in at least two orthogonal views, ideally centered at the 0° or 60° transducer position with a high-frequency transducer and a small field of view, with simultaneous biplane imaging and rotation through 180° as needed. Spontaneous echo contrast — echogenic, swirling reflections from genuinely low-velocity blood flow, visible as white swirls on the image — is itself associated with increased thrombus and embolic risk, independent of whether a discrete thrombus is actually seen.

LA appendage Doppler flow carries a specific, quotable threshold: with the pulsed Doppler sample volume positioned about 1 cm into the appendage, a normal contraction velocity is approximately 0.4 m/s — values below this are associated with increased thrombus formation risk. In atrial fibrillation, appendage flow becomes low-velocity and irregular rather than following this normal pattern, which is exactly the hemodynamic substrate that allows stasis and thrombus to develop.

On transthoracic imaging, if a discrete echogenic mass is seen in the LA of a patient with mitral stenosis and atrial fibrillation, specificity for thrombus is high — but TTE sensitivity for LA thrombus is very poor, and a negative transthoracic study in a patient where the diagnosis is genuinely suspected does not exclude the possibility.

Clinical Context Determines Whether the Finding Actually Matters

The importance of a demonstrated LA thrombus depends entirely on the clinical setting — the same finding can be decision-critical in one context and largely academic in another:

• In a patient with new atrial fibrillation and an embolic stroke, LA thrombus is the presumed cause whether or not one is actually imaged — demonstrating it (or failing to) is unlikely to change the decision to anticoagulate.
• In a patient with rheumatic mitral stenosis, a demonstrated LA thrombus is an outright contraindication to balloon mitral valvotomy — here, the finding is genuinely decision-changing.
• TEE evaluation for LA thrombus is also routinely performed before elective cardioversion, and before interventional or electrophysiology procedures placing catheters or devices in the LA, such as atrial fibrillation ablation or mitral valvuloplasty.

TEE-guided cardioversion — confirming no LA thrombus before proceeding — abolishes the conventional three-week period of pre-cardioversion anticoagulation in appropriately selected patients, a genuinely practical clinical pathway worth knowing explicitly.

Right Heart Thrombi

A Genuinely Underrecognized, Climbing-Incidence Entity

Right heart thrombi (RHT) are relatively common but easily missed without careful technique and a high index of suspicion — complicated further by inconsistent terminology (thrombus-in-transit, free-floating right heart thrombus, right-sided intracardiac thrombus) that itself contributes to variable incidence reporting across studies. Incidence is expected to climb with increasing use of right heart catheters, pacemakers, and other devices, alongside a growing population of adults with congenital heart disease and end-stage heart failure.

Incidence rises sharply with pulmonary embolism severity — a genuinely important, risk-stratified pattern: in hemodynamically stable PE, RHT occurs in about 2–3% of patients; in unstable or massive PE, incidence rises as high as 18%. In one registry using echocardiography within 48 hours of admission, overall RHT incidence was 4.5%, breaking down to 0.3% in low-risk, 3.8% in intermediate-risk, and 16% in high-risk patients. Mechanistically, RHT associated with PE are generally thought to represent thrombus-in-transit from the deep venous system toward the pulmonary vasculature — though some thrombi genuinely form in situ within the RA or RV, as can occur with catheter- or cardiomyopathy-associated thrombosis specifically.

Risk Factors Span Patient, Disease, Device, and Drug Categories

Patient characteristics	Disease state	Catheter or device	Drug or substance
Male sex, age ≥65	Malignancy, COPD	Central venous catheter	Amphotericin B
Hypercoagulable state, obesity	Chronic hemodialysis, CHF	Pacemaker (especially temporary)	Parenteral nutrition
Immobility, pregnancy	Atrial fibrillation/flutter	Multiple devices	No thromboprophylaxis
Trauma or surgery	Cardiomyopathy, cor pulmonale	PICC (size-dependent)	Cigarettes
Protein C/S deficiency	RV contusion or infarct	Internal jugular or subclavian location	Oral contraceptives
Thrombophilia, antiphospholipid syndrome	ARVC, IBD, Behçet disease	Distal position; duration beyond 6 days

Specific High-Risk Populations Worth Knowing

• Central venous catheters: used in up to 8% of hospitalized patients, with thrombotic complications in up to 66% of those with a catheter. Catheter-related RHT is identified at autopsy in up to 29% of cases where a CVC was present at death; by live TTE, up to 9% in children with malignancy and up to 18% in hemodialysis catheter patients. No formal management guidelines exist, though catheter removal plus 3–6 months of anticoagulation is the most commonly recommended approach, extrapolated from upper-extremity venous thrombosis guidelines.
• Right ventricular assist devices: pump thrombosis — a devastating complication often requiring pump exchange — occurs in over 30% of patients with severe RV failure requiring an RVAD, more common than the equivalent LVAD complication.
• Fontan physiology: intracardiac thrombus incidence of 8–13%, with 1-year mortality approaching 20% and nearly 40% showing residual clot on repeat imaging regardless of treatment strategy (anticoagulation, fibrinolysis, or surgery) — see Tricuspid Atresia and Pediatric Transthoracic Echocardiography for the broader single-ventricle physiology this risk profile sits within.
• Eisenmenger syndrome: pulmonary arterial thrombosis in about 20% of patients in vivo and 25% at necropsy — anticoagulation is necessary but genuinely controversial given these patients’ concurrent hemoptysis risk, making treatment decisions individualized rather than protocol-driven.
• Children: a meta-analysis of 122 pediatric RA thrombus cases found 91% were CVC-associated. A specific, memorable morphologic risk framework identifies high-risk thrombi: a snakelike shape, pedunculated attachment, excessive mobility, or size over 2 cm. Children with these high-risk features had meaningfully higher mortality (17%, 3 of 18) than those without (0%, 0 of 32) — morphology itself carries real prognostic weight, not just thrombus presence.

Identification

2D TTE remains the primary, initial diagnostic tool given its portability and real-time cross-sectional detail — but TEE is more sensitive for small thrombi, and better visualizes the superior and inferior venae cavae entering the RA. For RA thrombi specifically, reported sensitivities are approximately 97% for TEE versus 60% for TTE — TEE’s superiority is most evident in congenital heart disease, post-cardiac-surgery patients, and evaluation around indwelling catheters and devices. Intracardiac echocardiography (ICE), used during catheter-based interventions, is considered essentially 100% sensitive for RA masses, though its invasive nature limits routine use. CMR is the reference standard for classifying cardiac masses generally, with CT an acceptable alternative — though TTE typically remains the initial tool in practice, and most CMR studies are still performed with prior echocardiographic interrogation guiding the question being asked.

A specific right-heart differential worth distinguishing from true thrombus: Eustachian valve remnants (thin, linear, mobile structures at the cavoatrial junction), a Chiari network (a larger remnant spanning a greater length of the RA), and microbubbles from indwelling venous access, which characteristically appear in a different location on successive cardiac cycles — see Approach to Cardiac Masses for the complete normal-variant differential this fits into.

Cardiac Source of Embolism: The Broader Workup

Basic Principles

When a systemic embolic event is suspected to have a cardiac origin, echocardiographic evaluation is directed at three categories of finding, plus a fourth extracardiac consideration:

1. Abnormal intracardiac masses — LV or LA thrombus, LA tumor (especially myxoma), or valvular vegetation.
2. Abnormalities that predispose to intracardiac thrombus formation — LV aneurysm, mitral stenosis, atrial flow stasis — even when no thrombus is actually seen at the time of the study.
3. Cardiac conduits for paradoxical embolism — patent foramen ovale, atrial septal defect. See Atrial Septal Defect for the broader shunt physiology this mechanism depends on.
4. Aortic atheroma, with or without a protruding thrombus — an extracardiac but still echocardiographically assessable source.

A genuinely humbling statistic worth knowing explicitly: a definite cardiac source is identified by TTE in only about 10% to 15% of sequential patients with a suspected systemic embolic event. This partly reflects timing — imaging often occurs after the causative thrombus has already embolized and is no longer present — and partly reflects that the true source was extracardiac all along (aortic or carotid atheroma, for instance). In patients with atrial fibrillation and a systemic embolic event, LA thrombus formation is considered so likely that anticoagulation is appropriate even when TEE fails to demonstrate a clot directly — the clinical presumption outweighs a single negative imaging study.

Paradoxical Embolism and the PFO Workup

In fetal circulation, the fossa ovalis functions as a flap valve directing oxygenated placental blood from the RA to the LA; this flap typically fuses within the first few days after birth. When it remains unfused, it stays functionally closed because LA pressure normally exceeds RA pressure — but transient RA pressure elevation (coughing, Valsalva) or chronic RA pressure elevation (after pulmonary embolism, or with chronic lung disease) can produce right-to-left passage of blood, or thrombus, across the septum.

• An interatrial septal aneurysm is formally defined as fossa ovalis excursion greater than 15 mm from the septal plane, in the absence of chronically elevated LA or RA pressure, and carries up to a 90% likelihood of an associated fenestration — a direct conduit for paradoxical embolism in its own right.
• Color Doppler alone detects a PFO in only about 5–10% of cases by TEE, and less often by TTE — contrast (agitated saline) injection substantially improves detection by opacifying the right heart.
• At rest, contrast echocardiography detects a PFO in approximately 5% of the general population; with a provocative maneuver (such as release-phase Valsalva) performed simultaneously with contrast injection, detection rises to roughly 25% — consistent with PFO’s known general-population prevalence.

A properly performed saline contrast study should: use a view where right-heart contrast won’t shadow the left atrium; demonstrate left heart contrast appearance within three cardiac cycles of right heart opacification — this specific timing window is the key criterion separating a true intracardiac shunt from a pulmonary (intrapulmonary) one, where appearance is characteristically slower; record a sufficiently long clip to confirm correct timing; perform at least two injections, one at rest and one with a provocative maneuver; and consider proceeding to TEE whenever the result would genuinely change management.

Other Recognized Sources

• Congenital heart disease with atrial dilation or ventricular dysfunction carries real paradoxical embolism risk, particularly with a large ASD. Thrombi can pass RA to LA even with a predominantly left-to-right shunt, through flow streaming or transient pressure gradient shifts. In Eisenmenger complex with a large VSD, systemic embolization from peripheral venous thrombus is a recognized risk; this is unlikely with a small VSD, since high LV (relative to RV) pressure limits right-to-left flow.
• Prosthetic valves — mechanical valves carry higher clinical embolic event rates than tissue valves. Small prosthetic valve thrombi are genuinely difficult to visualize even on TEE, given shadowing and reverberation from the prosthetic material itself — diagnosis is often presumptive, based on evidence of suboptimal anticoagulation or exclusion of other causes, even when anticoagulation appeared adequate. The echo exam’s primary goals in this setting are assessing prosthetic valve function directly (since significant thrombus often causes stenosis, regurgitation, or both) and excluding other intracardiac thrombus sources.

How to Approach a Suspected Thrombus or Embolic Source: A Practical Sequence

1. Match the imaging modality to the suspected chamber — TTE first and foremost for LV thrombus; TEE when LA or RA thrombus is genuinely in question, since TTE’s sensitivity in those locations is poor enough to be unreliable on its own.
2. Confirm the formal diagnostic criteria for LV thrombus specifically: convex surface, distinct from endocardium, not a reverberation artifact, located in a region of abnormal wall motion — and use contrast opacification whenever apical visualization is suboptimal.
3. Assess morphology, not just presence — protruding or mobile thrombus (LV), or high-risk morphologic features like a snakelike shape or size over 2 cm (pediatric RA thrombus), both carry independently higher embolic or mortality risk than sessile, small, low-risk morphology.
4. Weigh clinical context directly when a thrombus is found — the same LA thrombus finding is largely academic in AF-related stroke but outright procedure-gating in rheumatic mitral stenosis.
5. When working up a suspected embolic source, systematically assess all three intracardiac categories plus aortic atheroma, and remember that a negative study occurs in roughly 85–90% of cases — a negative result doesn’t mean the source wasn’t cardiac, only that it wasn’t demonstrated.
6. For suspected paradoxical embolism, perform a technically correct saline contrast study — right or provocative views that avoid LA shadowing, the three-cycle timing criterion, adequate clip length, and both a resting and a provoked injection — before concluding a PFO is genuinely absent.
7. Consider right heart thrombus actively in the right clinical context — significant PE, indwelling catheters or devices, Fontan or Eisenmenger physiology, or pediatric malignancy — rather than treating it as a rare finding not worth deliberately searching for.

Clinical Importance

Thrombus is the one member of this section’s tumor/thrombus/vegetation triad where getting the imaging modality right is itself half the diagnosis — a technically excellent TEE can still miss an LV apical clot that a basic TTE would catch, and the reverse is just as true for the left atrial appendage. Pairing the right modality with the right chamber, reading morphology as a genuine risk signal rather than a binary present-or-absent finding, and remembering that a negative embolic-source workup is common rather than reassuring, together form the actual discipline this page is built around.